Related Experiment Videos
Adipokines and liver fibrosis
F Marra1, S Aleffi, C Bertolani
1Dipartimento di Medicina Interna, Transfer, and High Education MCIDNENT, University of Florence, Italy.
European Review for Medical and Pharmacological Sciences
|October 20, 2005
Summary
Liver fibrosis is a wound healing response to chronic liver injury. Adipokines, like leptin, may clarify mechanisms of non-alcoholic steatohepatitis (NASH) progression and inform patient management.
Area of Science:
- Hepatology
- Cell Biology
- Metabolic Syndrome
Background:
- Liver fibrosis is a complex cellular response to chronic liver injury, involving inflammation and matrix deposition.
- Hepatic stellate cells (HSC) activate into myofibroblast-like cells, synthesizing extracellular matrix components.
- Obesity is linked to non-alcoholic steatohepatitis (NASH) and independently promotes fibrosis progression.
Purpose of the Study:
- To explore the role of adipokines in the progression of liver fibrosis, particularly in NASH.
- To understand how adipokines secreted by adipocytes and liver cells influence liver disease mechanisms.
- To identify potential therapeutic targets for managing chronic liver disease.
Main Methods:
- Review of clinical and experimental findings on adipokines in liver disease.
- Analysis of the biological actions of leptin, adiponectin, and resistin in liver fibrosis.
- Correlation of adipokine activity with disease progression in NASH.
Main Results:
- Adipokines, including leptin, adiponectin, and resistin, play a significant role in liver disease.
- These molecules may mediate the progression of fibrosis in NASH.
- Understanding adipokine function is crucial for deciphering disease mechanisms.
Conclusions:
- Adipokines are key players in the pathogenesis of liver fibrosis, especially in NASH.
- Further research into adipokines could lead to improved management strategies for chronic liver disease.
- Targeting adipokine pathways may offer novel therapeutic avenues.